GASTRIC CANCER

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults will be enrolled and their outcomes compared to those treated with standard stents or …

This study is testing whether a newer, less invasive type of stomach cancer surgery (using just one or a few small cuts) is as safe and effective as the standard approach. The trial involves 108 people with advanced stomach cancer who need their stomach partially removed. The mai…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This early-phase study is testing whether a diet low in the amino acid leucine, given for just three days before surgery, is safe for people with stomach cancer. Researchers will check blood amino acid levels, immune cell changes, and any side effects. The goal is to see if this …

This early-phase trial tests a new drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in 87 people with advanced stomach cancer. The main goal is to find the safest dose and check for side effects. It is not yet known if the combination works better th…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…

This phase 2 trial tests whether adding an experimental drug (ONO-4578) to standard immunotherapy (nivolumab) and chemotherapy helps people with advanced HER2-negative stomach cancer. About 226 participants who have not had prior chemotherapy will receive either the experimental …

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…

This study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment works just as well to prevent cancer from coming back, while causing fewer side effects. Partic…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical remov…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study tests a new drug (RC48-ADC) combined with immunotherapy (toripalimab) and either chemotherapy or another targeted drug (trastuzumab) as a first treatment for people with advanced stomach cancer. About 201 adults aged 18-75 with HER2-positive or HER2-negative stomach ca…

This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…

This study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for …

This study looks at whether a special type of CT scan (spectral CT) combined with a tumor marker (MSI status) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the CT results with the actual lymph node findings after surgery …

This study tests a new magnetic tracer, FerroTrace, to find sentinel lymph nodes in people with stomach or esophageal cancer. About 60 participants will receive the tracer before standard treatment, and doctors will compare its accuracy to current methods. The goal is to see if t…

This study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and gastric cancer. Those who test positive receive free treatment with a three-drug combination (VOQUEZNA® Triple Pak®) for 14 days. The goal is to see i…

This study screens people in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and even stomach cancer. Those who test positive receive treatment, and the study compares at-home breath testing versus in-person retesting to confirm the in…

This study tests whether personalized screening can prevent stomach and colon cancer in 40,000 healthy adults aged 50-75. For stomach cancer, researchers combine a test for H. pylori bacteria with a blood test for stomach damage to identify high-risk individuals. For colon cancer…

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This trial compares two surgeries—removing part of the stomach (resection) versus creating a bypass—to relieve blockages in advanced stomach cancer. It includes 63 patients with obstructed tumors. The main goal is to see which procedure better eases symptoms like nausea and vomit…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests a surgical technique called a jejunal pouch in 26 adults who need their entire stomach removed due to cancer or a high-risk gene mutation. The pouch is created from a section of the small intestine to replace the stomach's reservoir function. The goal is to reduc…

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at genetic changes in people with H. pylori infection or stomach cancer to understand how the infection can lead to cancer. Researchers will analyze tissue samples from 110 adults undergoing endoscopy. The goal is to find early warning signs and possible ways to …

This study looks at how anemia changes blood flow in the smallest blood vessels (microcirculation) in patients having open surgery for gastric cancer. Researchers will compare 27 anemic patients with 27 non-anemic patients, all receiving standard goal-directed fluid therapy. They…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This study tests whether an artificial intelligence (AI) model can help pathologists diagnose gastric cancer more accurately and quickly. About 1000 patients with gastric biopsies or surgical samples will take part. Some pathologists will use the AI tool to assist their diagnosis…

This study looks back at 193 people with stomach, appendix, or colon cancer who had surgery with or without heated chemotherapy (HIPEC). Researchers want to see if HIPEC affects how quickly the bowels start working again after surgery and whether it leads to more complications. T…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …